NerLYNX nunini approved for extended assisted treatment for HER2-positive breast cancer patients
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
CANbridge Pharmaceuticals announced that its tyrosine kinase inhibitor NERLYNX (Neratinib) has been approved by the National Drug Administration (NMPA) for extended complementary treatment for adult patients with early HER2-positive breast cancer treated with qutomono-assisted treatmentCANbridge acquired THE exclusive development and commercial rights of NERLYNX in China from Puma Biotechnology in 2018founder, Dr James Xue, said: 'Thanks to Puma's partnership, coupled with the positive response from NMPA, we were able to get our approval only 18 months after submissionThe NMPA approval is the first time that women with early-stage breast cancer in the country have access to this oral-assisted treatmentPuma Biotechnology CEO and President Alan HAuerbach added: 'Reducing the risk of recurrence in HER2-positive early breast cancer patients is criticalThe NMPA's approval is an important milestone and we thank and congratulate CANbridgeTheabout 20 to 25 percent of breast cancer tumors over-expressing HER2 proteinHER2-positive breast cancer is usually more aggressive than other types of breast cancer, which increases the risk of disease progression and deathAlthough studies have shown that qutobeu-behrendt can reduce the risk of early breast cancer recurrence after surgery HER2, up to 25% of patients treated with qutobeumono resistance will relapse
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
